Navigation Links
WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
Date:11/8/2010

SHANGHAI, Nov. 8, 2010 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good Laboratory Practice (GLP) compliance from the State Food and Drug Administration (SFDA), China's regulatory authority for pharmaceuticals, for its toxicology facility in Suzhou.  Good Laboratory Practice is a quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported.

(Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO)

The certification covers single-dose and multiple-dose toxicology studies in both rodents and non-rodents, GeneTox studies (Ames, micronucleus, and chromosome aberration), and toxicokinetic studies.  WuXi qualified for this certification as a result of SFDA review of its management, personnel, test facilities, standard operating procedures, and study operations.  Receipt of this certification is necessary in order to perform toxicology studies to be filed in Investigational New Drug (IND) applications with the SFDA.

In September, WuXi announced that the Suzhou facility had received GLP certification from the Organization for Economic Cooperation and Development.  WuXi's Suzhou facility is the only toxicology facility in China to have received certification from both the SFDA and OECD.

"This certificate from the SFDA is an important milestone in offering our clients toxicology studies that meet both domestic and international GLP quality standards for filing INDs both in China and other countries," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech.  "With this award, WuXi moves a step closer to achieving its goal of offering our pharmaceutical and biotech clients a comprehensive, fully integrated platform of pharmaceutical R&D services."

About WuXi PharmaTech WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit: http://www.wuxiapptec.com . For more information, please contact:Stephanie Liu (for the media)Tel:   +86-21-5046-4362Email: pr@wuxiapptec.comRonald Aldridge (for investors)Tel:   +1-201-585-2048Email: Ron_Aldridge@wuxiapptec.com
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Schedules Third-Quarter 2010 Earnings Conference Call
2. Professor Steven V. Ley Speaks at WuXi PharmaTech
3. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
4. WuXi PharmaTech Announces Second-Quarter 2010 Results
5. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
6. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
7. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
10. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
11. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):